National Core Facility for Biopharmaceuticals

iPSC

Human Disease Induced Pluripotent Stem Cells Service ConsortiumDr. Patrick C.H. Hsieh, Distinguished Research Fellow

As the medical sciences advance, the population age in Taiwan has become older and have longer life expectancy. Therefore, chronic diseases have gradually replaced infectious diseases and now become an important issue in public health. Since Taiwanese have distinctive genetic traits in addition to their unique lifestyle and pathogenic factors, it is necessary to establish human induced pluripotent stem cell databank in Taiwan. In 2015, the first and the only Taiwanese induced pluripotent stem cell (iPSC) core facility, named the Taiwan Human Disease iPSC Service Consortium, was formed to accelerate stem cell research and development by providing a core service platform for Taiwanese researchers interested in the iPSC field. Whether experienced or inexperienced, users can utilize iPSCs as tools for drug discovery or disease modelling – particularly on heart diseases, neural degenerative diseases, and retinal diseases - through directed differentiation. The consortium dedicates a portion of its budget towards education and training and has become a resource center for scientists across the nation. Thus far, 110 iPSCs have been banked and publicly deposited in our cell bank at BCRC. This not only allow us become the fifth ranking from the world SKIP project but also increase our awareness internationally.

https://ipsc.ibms.sinica.edu.tw/

Acknowledgment template：

We thank the Human Disease iPSC Service Consortium for iPSC generation and technical support. The Consortium is funded by the National Science and Technology Council (NSTC) (NSTC 112-2740-B-001-004).